Positive: Chronic pain clinical trial pipeline is experiencing momentum with promising therapies being evaluated
From GlobeNewswire: 2025-01-30 13:00:00
Chronic Pain Clinical Trial Pipeline Experiences Momentum:
DelveInsight estimates a diverse pipeline with 20+ companies working in the chronic pain domain. The rising prevalence of chronic pain drives market growth, encouraging investment in research and development for effective pain management solutions.
Key Takeaways from the Chronic Pain Pipeline Report:
The report depicts a robust space with 20+ active players developing 25+ pipeline chronic pain drugs. Companies like Apurano Pharmaceuticals, Centrexion Therapeutics, and Mesoblast are evaluating promising therapies like Adezunap and Rexlemestrocel-L in clinical trials.
Recent Advances in Chronic Pain Therapies:
Positive results from Tris Pharma’s ALLEVIATE-1 trial for cebranopadol in treating acute pain show promising efficacy. ANANDA Scientific Inc. is evaluating Nantheia™ ATL5 for co-occurring opioid use disorder and chronic pain, while Mesoblast is enrolling patients for a Phase III trial of rexlemestrocel-L for chronic low back pain.
Chronic Pain Overview:
Chronic pain can stem from various sources, including illnesses, injuries, or ongoing conditions like arthritis. It affects many aspects of life and requires a multidisciplinary approach for management. Treatment options range from over-the-counter medications to prescription opioids, with a focus on symptom relief and support.
Chronic Pain Therapeutics Assessment:
DelveInsight’s report provides a comprehensive view of emerging chronic pain therapies segmented by stage, product type, route of administration, and mechanism of action. It covers key companies like Apurano Pharmaceuticals, Centrexion Therapeutics, and Mesoblast, along with promising pipeline drugs like Adezunap and Rexlemestrocel-L.
Scope of the Chronic Pain Pipeline Report:
The report analyzes global therapeutic assessments based on product type, clinical stages, route of administration, molecule type, and mechanism of action. It includes key chronic pain companies and pipeline therapies, offering insights for stakeholders in the chronic pain domain.
Read more at GlobeNewswire: Chronic Pain Clinical Trial Pipeline Experiences Momentum: